Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.41 |
| ▸ | ATR | Q13535 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24142066 | 0.89 | CYP4F2 (0.41) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL24031809 | 0.85 | CYP4F2 (0.43) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL365094 | 0.84 | CYP4F2 (0.43) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL17129377 | 0.77 | CYP4F2 (0.38) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL24031824 | 0.76 | CYP4F2 (0.41) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL26199501 | 0.75 | CYP4F2 (0.40) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL15813615 | 0.73 | KDM5B (0.36) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL8004755 | 0.71 | CYP4F2 (0.53) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL21437982 | 0.70 | CYP4F2 (0.49) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL1527234 | 0.70 | SNCA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2023-06-08 | — | — | US | disclosed |
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2023-06-08 | — | — | US | disclosed |
| WO-2021229145-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174517-A1 | METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | AR, GNRHR, FSHR | CYP4F2 354/4885CYP4A11 126/4885ATR 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.